Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Sponsor
Hebei Medical University
Study ID
NCT02509806
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib Mesylate Tablets 500 mg qd p.o.

Study Details

The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after first-line chemotherapy in Postoperative Recurrence / Metastasis Progressive Gastric Cancer.

Key Dates

Start date
Jul 31, 2015
Status verified
Oct 2017
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Maintenance Therapy After First-line Chemotherapy
    Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
  • No Intervention: No Intervention After First-line Chemotherapy
    No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）

Primary Outcome Measure

Progression free survival [ Time Frame: An expected average of 12 weeks ]

Central Contacts

Related Studies